

Miltenyi Biotec

Copyright © Eye of Science

Generation of functional CAR T cells from CD4+ and CD8+ T cells

Background

T cells are central effectors of the immune system and play a pivotal role in the fight against cancer. Recently, T cells have been redirected against tumor cells by genetic engineering. Equipped with a transgenic chimeric antigen receptor (CAR) that recognizes a specific tumor antigen, CAR T cells are a promising new tool for a precise and efficient cancer therapy. However, optimal parameters for the generation, cultivation, and analysis of CAR T cells are still to be defined in order to translate the most efficient approaches into immunotherapy. Automation and easy translation from basic research into a clinical setting are particularly important challenges to address.

Here we demonstrate that human CD4+ and CD8+ T cells isolated with MACS® Technology are efficiently used to generate functional CAR T cells. MACS Technology enables fully automated cell separation with the autoMACS® Pro Separator, as well as straightforward translation into clinical settings thanks to MACS® GMP Products and the CliniMACS® Prodigy.

Method

T cells were isolated from peripheral blood mononuclear cells (PBMCs) with CD4+ and CD8+ MicroBeads, using the autoMACS® Pro Separator. The purity of isolated T cells was assessed by flow analysis using REAfinity™ Recombinant Antibodies and the MACSQuant® Analyzer. Enriched T cells were resuspended in TexMACS™ Medium supplemented with MACS® Cytokines (IL-7, IL-15) and the T cell activation reagent T Cell TransAct™ (day 1). After a 24 hour incubation period (day 2), T cells were transduced with the CD19 CAR construct using a lentiviral vector and incubated for 48 hours (day 4). On day 4, the cell culture supernatant, containing T Cell TransAct and the lentiviral vector, was removed. CAR T cells were expanded in TexMACS Medium supplemented with IL-7 and IL-15 for an additional 8 days with splitting every 2 to 3 days. On day 12, transduction efficiency was assessed by flow cytometry. Additionally, functionality and antigen specific target cell killing was assessed via a killing assay. Transduced T cells were co-cultured with either the GFP+CD19+ JeKo-1 mantle cell lymphoma target cell line or a GFP+CD19 knock out (k.o.) JeKo-1 variant control at indicated ratios. Using the MACSQuant Analyzer, the killing rate was determined by analyzing the green fluorescent protein (GFP) fluorescence intensity of the target cells or control cells respectively.

Results

Isolated CD4+ and CD8+ T cells exhibited a purity of >98% (fig. 1B). After transduction and expansion, cells were analyzed for CD4+, CD8+, and expression of CD19 CAR. More than 99% of all viable leucocytes were CD4+ or CD8+ (based on CD45 expression, 7-AAD fluorescence, and scatter signal) and more than 56% of all CD3+ cells expressed the CD19 CAR construct (fig. 2B).



Figure 1: Flow cytometry analysis of T cells. CD4+ and CD8+ T cells before (A) and after (B) separation on day 1.



Figure 2: CD4+, CD8+ and CAR expression of transduced T cells after expansion on day 12.

CD19 CAR T cells were functionally tested in a killing assay. Flow cytometry analysis showed approximately 80% killing of target cells (GFP$^+$CD19$^+$ JeKo-1) at a 5-fold excess of CD19-directed CAR T cells (fig. 3). When changing the ratio by decreasing the number of CAR T cells, a maximum of 18% of the target cells were killed. In contrast, the GFP$^+$CD19$^+$ JeKo-1 control cells were not killed by the CD19 CAR T cells, highlighting the specificity of the CAR T cells.



Figure 3: Killing of GFP$^+$CD19$^+$ JeKo-1 target cells by CD19 CAR T cells in a ratio-dependent manner. CAR T cells were derived from isolated CD4$^+$ and CD8$^+$ T cells from three independent donors (A, B, and C).

Conclusion

The autoMACS® Pro Separator provides an automated solution to isolate pure CD4$^+$ and CD8$^+$ T cells for manufacturing functional CAR T cells. It enables reliable, fully automated separation of T cells from PBMCs with minimal hands-on time. Minimal labelling ensures preservation of T cell functionality, enabling downstream compatibility for CAR T cell generation.

See more and download our **poster:**
Automated manufacturing of gene-engineered T cells under serum-free conditions
www.miltenyibiotec.com/cart-poster

Take a look at our **detailed workflow protocol:**
Engineering of CAR T cells for research use
www.miltenyibiotec.com/car-t-protocol

Product	Order no.
autoMACS® Pro Separator	130-092-545
CD4 MicroBeads, human	130-045-101
CD8 MicroBeads, human	130-045-201
TexMACS™ Medium	130-097-196
Human IL-7, premium grade	130-095-361
Human IL-15, premium grade	130-095-762
T Cell TransAct™, human	130-111-160
MACSQuant® Analyzer 10	130-096-343
7-AAD Staining Solution	130-111-568
REAfinity™ Recombinant Antibodies	**www.miltenyibiotec.com/antibodies**

Miltenyi Biotec

Miltenyi Biotec GmbH | Phone +49 2204 8306-0 | Fax +49 2204 85197 | macs@miltenyibiotec.de | **www.miltenyibiotec.com**
Miltenyi Biotec provides products and services worldwide. Visit **www.miltenyibiotec.com/local** to find the nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.
MACS® GMP Products are for research use and *ex vivo* cell culture processing only, and are not intended for human *in vivo* applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS® System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. autoMACS, MACS, MACSQuant, REAfinity, TexMACS, TransAct, and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. Copyright © 2019 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.

V.01